Synthetic Biologics Overview

  • Founded
  • 2001

Founded
  • Status
  • Public

  • Employees
  • 16

Employees
  • Stock Symbol
  • SYN

Stock Symbol
  • Investments
  • 3

  • Share Price
  • $1.47

  • (As of Friday Closing)

Synthetic Biologics General Information

Description

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
ASE
Primary Office
  • 9605 Medical Center Drive
  • Suite 270
  • Rockville, MD 20850
  • United States
+1 (301) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synthetic Biologics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.47 $1.42 $1.35 - $5.58 $23.3M 15.8M 193K -$1.22

Synthetic Biologics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (21,123) (37,391) 14,758 5,111
Revenue 0 0 0 0
EBITDA (17,741) (14,187) (9,959) (15,423)
Net Income (17,777) (14,267) (10,043) (15,303)
Total Assets 82,331 70,365 8,410 17,235
Total Debt 1,698 1,527 473 722
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Synthetic Biologics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synthetic Biologics‘s full profile, request access.

Request a free trial

Synthetic Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfol
Drug Discovery
Rockville, MD
16 As of 2021
000.00
000000000 000.00

0000 0

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
0000 000000000
Somerville, MA
0 As of 0000
00.00
00000000000 00.00

000000

oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synthetic Biologics Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xeno Biosciences Venture Capital-Backed Somerville, MA 0 00.00 00000000000 00.00
00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000000 00000
00000000 Formerly VC-backed Roseville, MN 00 000.00 000000&0 000.00
00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed Wayne, PA 0 000.00 00000000000 000.00
You’re viewing 5 of 38 competitors. Get the full list »

Synthetic Biologics Patents

Synthetic Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3999637-A1 Intestinal alkaline phosphatase-based treatments of metabolic disorders Pending 18-Jul-2019 000000000
CA-3146738-A1 Intestinal alkaline phosphatase-based treatments of metabolic disorders Pending 18-Jul-2019 000000000
AU-2020287084-A1 Alkaline phosphatase formulations and uses thereof Pending 03-Jun-2019 0000000000
EP-3975999-A1 Alkaline phosphatase formulations and uses thereof Pending 03-Jun-2019 0000000000
CA-3142240-A1 Alkaline phosphatase formulations and uses thereof Pending 03-Jun-2019 A61K9/1623
To view Synthetic Biologics’s complete patent history, request access »

Synthetic Biologics Executive Team (11)

Name Title Board Seat Contact Info
Steven Shallcross Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director
Frank Tufaro Ph.D Chief Operating Officer, Operations
Vince Wacher Ph.D Contractor
Sheila Connelly Ph.D Vice President of Research
You’re viewing 4 of 11 executive team members. Get the full list »

Synthetic Biologics Board Members (4)

Name Representing Role Since
0000000 00000 Self Chairman 000 0000
0000000 0000 00 Self Board Member 000 0000
0000 0000000 00.0 Synthetic Biologics Board Member 000 0000
00000 0000000 Self Board Member 000 0000
To view Synthetic Biologics’s complete board members history, request access »

Synthetic Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synthetic Biologics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Synthetic Biologics‘s full profile, request access.

Request a free trial

Synthetic Biologics Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 10-Mar-2022 0000000000 000.00 Drug Discovery 000000 00
0000 000 (000 28-Nov-2012 000000000 000.00 Buildings and Property 0000000 0
Adeona Pharmaceuticals 16-Feb-2012 Merger/Acquisition Pharmaceuticals
To view Synthetic Biologics’s complete investments and acquisitions history, request access »

Synthetic Biologics Subsidiaries (1)

Company Name Industry Location Founded
000 00000000000 Drug Discovery Barcelona, Spain 0000
To view Synthetic Biologics’s complete subsidiaries history, request access »